Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
Crossref DOI link: https://doi.org/10.1007/s12325-019-00945-2
Published Online: 2019-04-12
Published Print: 2019-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Johansen, Pierre
Hunt, Barnaby http://orcid.org/0000-0001-5420-279X
Iyer, Neeraj N.
Dang-Tan, Tam
Pollock, Richard F.
Text and Data Mining valid from 2019-04-12
Article History
First Online: 12 April 2019